Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.69 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.69 |
| ▸ | PRKAB2 | O43741 | 8/20 | 0.62 |
| ▸ | PRKAG1 | P54619 | 8/20 | 0.62 |
| ▸ | PRKAA2 | P54646 | 8/20 | 0.62 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.62 |
| ▸ | PRKAG3 | Q9UGI9 | 8/20 | 0.62 |
| ▸ | PRKAG2 | Q9UGJ0 | 8/20 | 0.62 |
| ▸ | PRKAB1 | Q9Y478 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18083682 | 0.89 | HIF1A (0.58) | HIF1AEPAS1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL5546576 | 0.89 | L3MBTL1 (0.62) | HIF1AEPAS1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL17066302 | 0.88 | NPC1 (0.62) | HIF1AEPAS1PRKAA2MAPTFAAH | |
| SCHEMBL23632422 | 0.85 | MAPT (0.63) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL18083681 | 0.83 | ACKR3 (0.54) | HIF1AEPAS1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL23167662 | 0.83 | L3MBTL1 (0.55) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL18083772 | 0.80 | SMN1; SMN2 (0.64) | HIF1AEPAS1MAPTFAAHKDM4E | |
| SCHEMBL20684900 | 0.80 | ACKR3 (0.56) | HIF1AEPAS1MAPTFAAHRAB9A | |
| SCHEMBL1943768 | 0.80 | MAPT (0.93) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL377536 | 0.80 | VEGFA (0.53) | MAPTFAAHALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271348-B1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2019-01-30 | — | — | EP | disclosed |
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2018-04-26 | — | — | US | disclosed |
| WO-2016146220-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2016-09-22 | — | — | WO | disclosed |
| EP-3070084-A1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2016-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | FYN, LCK, LYN | HIF1A 2440/4885EPAS1 2013/4885PRKAB2 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.